Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod IncfiledCriticalPfizer Prod Inc
Priority to UY26417ApriorityCriticalpatent/UY26417A1/en
Publication of UY26417A1publicationCriticalpatent/UY26417A1/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Cristales inhibidores del NHE-1, procedimientos de uso de tales cristales inhibidores del NHE-1 y composiciones farmacéuticas que contienen tales cristales inhibidores del NHE-1. Los cristales inhibidores del NHE-1 son útiles para reducir la lesión en los tejidos originada por una isquemia en los tejidos.NHE-1 inhibitor crystals, methods of using such NHE-1 inhibitor crystals, and pharmaceutical compositions containing such NHE-1 inhibitor crystals. NHE-1 inhibitor crystals are useful for reducing tissue damage caused by tissue ischemia.
UY26417A2000-10-252000-10-25
TYPE 1 SODIUM-HYDROGEN EXCHANGER INHIBITOR CRYSTALS
UY26417A1
(en)
GUANIDINE DERIVATIVES OF ETANOLATE INHIBITORS OF THE SODIUM-HYDROGEN EXCHANGER OF TYPE 1; COMPOSITIONS; PREPARATION AND USE PROCEDURE IN THE PREPARATION OF MEDICINES
NPTICALLY ACTIVE DERIVATIVES OF 2-AMINOTETRALINA, PROCESSES FOR THE PREPARATION OF THEM AND THERAPCUTIC USE OF PHARMACCUTIC COMPOSITIONS CONTAINING THEM